Kiniksa Pharmaceuticals (KNSA) Stock Price Target 2026

The average analyst price target for Kiniksa Pharmaceuticals is $87.30, 8.8% below the current price. Of 9 analysts, 9 rate it Buy. Targets range from $35 to $122. The latest change came on Oct 30, 2026, when JP Morgan raised its price target on Kiniksa Pharmaceuticals from $107 to $122 and kept an Overweight rating.

The Average Analyst Price Target for Kiniksa Pharmaceuticals is $87.30.

Price Target Range — 12 Quarters

Analyst Consensus — 9 Analysts

9Buy

Consensus RatingBuy# Analysts9Avg. Consensus PT$87.30Upside to Avg. PT-8.8%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Kiniksa Pharmaceuticals Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 30, 2026	JP Morgan	Anupam Rama	PT Raise	Overweight	$107→$122
Oct 28, 2026	Goldman Sachs	Paul Choi	PT Raise	Buy	$90→$101
Oct 28, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$99→$102
Oct 28, 2026	Wells Fargo	Yanan Zhu	PT Raise	Overweight	$87→$110
Jul 30, 2026	Goldman Sachs	Paul Choi	PT Raise	Buy	$75→$90
Jul 29, 2026	JP Morgan	Anupam Rama	PT Raise	Overweight	$72→$107
Jul 29, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$64→$98
Jul 29, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$72→$99
Jul 29, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$60→$100
Jul 23, 2026	Goldman Sachs	Paul Choi	PT Raise	Buy	$60→$75
Jul 13, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Overweight	$57→$74
Jun 29, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$59→$72
Apr 29, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$62→$64
Apr 29, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$50→$60
Apr 29, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$58→$59
Apr 29, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Overweight	$53→$57
Apr 28, 2026	Jefferies	Roger Song	PT Raise	Buy	$58→$71
Apr 16, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$53→$58
Feb 25, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Overweight	$50→$53
Feb 25, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$50→$53

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $122

JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $107 to $122.

Benzinga Newsdesk

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $101

Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $90 to $101.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $102

Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $99 to $102.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $110

Wells Fargo analyst Yanan Zhu maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $87 to $110.

Benzinga Newsdesk

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $75 to $90.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107

JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $72 to $107.

Benzinga Newsdesk

Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals (KNSA) Stock Price Target 2026

The Average Analyst Price Target for Kiniksa Pharmaceuticals is $87.30.

Latest Upgrades and Downgrades for Kiniksa Pharmaceuticals Stock

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $122

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $101

PRO
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $102

PRO
Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $110

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107

People Also Watch

People Also Watch

Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals (KNSA) Stock Price Target 2026

The Average Analyst Price Target for Kiniksa Pharmaceuticals is $87.30.

Latest Upgrades and Downgrades for Kiniksa Pharmaceuticals Stock

Analyst Ratings News

PROJP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $122

PROGoldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $101

PROWedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $102

PROWells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $110

PROGoldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

PROJP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107

People Also Watch

People Also Watch

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $122

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $101

PRO
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $102

PRO
Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $110

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107